



Symic Bio to Present at the 11th Annual BIO-Europe Spring Conference

SAN FRANCISCO, March 13, 2017 – Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, today announced that Rinko Ghosh, President and Chief Business Officer, will present an overview of current programs at the upcoming 11th Annual BIO-Europe Spring Conference.

Conference details are as follows:

Date: Tuesday, March 21, 2017

Time: 11:45 a.m. CET

Location: CCIB Convention Centre, Barcelona, Spain

About Symic Bio

Symic Bio is a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which will initially target the prevention of peripheral vein graft failure and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contacts

Gitanjali Jain Ogawa
The Trout Group
(646) 378-2949
gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
david.schull@russopartnersllc.com
rich.allan@russopartnersllc.com